Stay updated on Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The clinical trial record for umbralisib and pembrolizumab is displayed, with study details, results, eligibility criteria, and supporting documents. The record indicates that the trial was terminated and is no longer recruiting participants.
    Difference
    51%
    Check dated 2026-11-08T13:28:05.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The 403 error message and its Home link disappeared, while the study page’s main content area appears blank. The site revision changed from v3.7.2 to v3.8.0.
    Difference
    0.6%
    Check dated 2026-11-01T14:11:19.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    A banner announces NIH website transition updates and a change in terminology from “Artificial Intelligence” to “Super Intelligence.” The page content remains a 403 error.
    Difference
    1%
    Check dated 2026-10-25T13:40:18.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-18T15:13:21.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The footer site revision changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-11T14:24:10.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study record, indicating the content is currently inaccessible. This replaces the expected study details and documents with a standard access-denied message.
    Difference
    19%
    Check dated 2026-09-20T20:47:23.000Z thumbnail image

Stay in the know with updates to Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.